# Navignostics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/navignostics

- Industry: Biotechnology
- Headquarters: Zurich, Switzerland
- Website: www.navignostics.com
- Total disclosed funding: $7.9M
- Latest round: Seed (Nov 9, 2022)
- Investors on record: 4

## About

Based in Zurich, Switzerland, and founded in 2022 by Andrea Jacobs, Jana Fischer, Stephane Chevrier, and Bernd Bodenmiller, Navignostics AG, a.k.a. Navignostics operates as a developer of a biotechnology research platform that focuses on the development of treatments for patients with cancer. In November 2022, Navignostics AG raised CHF 7.5 million in seed funding led by Bruker Invest AG, with participation from Think.Health Ventures, Ventura BioMed Investors, and Zürcher Kantonalbank Asset Management.

The company’s investigative (analytic) procedures detect proteins that characterize tumors by staining cancer tissues with panels of over 40 selected metal-labeled antibodies. These antibodies are detected with an imaging mass cytometry system that measures the metal signals corresponding to each of the proteins of interest in a single step and offers key insights, which extracts tumor features ranging from single-cell protein expressions to cell types, to cellular interactions and assemblies that clarify drug and disease mechanisms, provide individualized drug treatment suggestions and identify novel signatures.

The company plans to use its proceeds from November 2022 funding to accelerate its clinical trial as well as its product launch.

## Funding rounds

- Seed, Nov 9, 2022, $7.9M — Zürcher Kantonalbank Asset Management, Think.Health Ventures, Ventura BioMed Investors, Bruker Invest AG

## Investors

- Zürcher Kantonalbank Asset Management — Seed
- Think.Health Ventures (https://capitalatlas.ai/funds/think-health-ventures) — Seed
- Ventura BioMed Investors (https://capitalatlas.ai/funds/ventura-biomed-investors) — Seed
- Bruker Invest AG — Seed